Avanafil (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Avanafil" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

low place

low place

2semanticscholar.org

11^th place

8^th place

3,984^th place

2,622^nd place

399^th place

333^rd place

68^th place

117^th place

800^th place

676^th place

1web.archive.org

1^st place

1^st place

1medicinenet.com

3,840^th place

3,358^th place

doi.org

Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. 47 (10). Sage Publishing: 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Burke RM, Evans JD (2012). "Avanafil for treatment of erectile dysfunction: review of its potential". Vascular Health and Risk Management. 8: 517–523. doi:10.2147/VHRM.S26712. PMC 3433322. PMID 22973106.
Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. (August 2012). "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction". The Journal of Urology. 188 (2): 668–674. doi:10.1016/j.juro.2012.03.115. PMID 22704456.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

drugs.com

"Stendra FDA Approval History". Drugs.com. Retrieved 6 March 2021.

espacenet.com

worldwide.espacenet.com

US 6797709, Yamada K, Matsuki K, Omori K Kikkawa K, "Aromatic nitrogen-containing 6-membered cyclic compounds", issued 11 December 2003, assigned to Tanabe Seiyaku Co

europa.eu

ema.europa.eu

"Spedra (avanafil)". European Medicines Agency. Retrieved 17 April 2014.

medicinenet.com

"avanafil, Spedra". Medicine Net. Retrieved 17 April 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. 47 (10). Sage Publishing: 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Burke RM, Evans JD (2012). "Avanafil for treatment of erectile dysfunction: review of its potential". Vascular Health and Risk Management. 8: 517–523. doi:10.2147/VHRM.S26712. PMC 3433322. PMID 22973106.
Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. (August 2012). "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction". The Journal of Urology. 188 (2): 668–674. doi:10.1016/j.juro.2012.03.115. PMID 22704456.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

ncbi.nlm.nih.gov

Burke RM, Evans JD (2012). "Avanafil for treatment of erectile dysfunction: review of its potential". Vascular Health and Risk Management. 8: 517–523. doi:10.2147/VHRM.S26712. PMC 3433322. PMID 22973106.

semanticscholar.org

api.semanticscholar.org

Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. 47 (10). Sage Publishing: 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

vivus.com

ir.vivus.com

"VIVUS Announces Avanafil Partnership With Menarini". Vivus Inc. Archived from the original on 2015-12-08.
"VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to Stendra". Vivus Inc. 3 October 2016.

web.archive.org

"VIVUS Announces Avanafil Partnership With Menarini". Vivus Inc. Archived from the original on 2015-12-08.